HomeCompareARSSF vs KMB

ARSSF vs KMB: Dividend Comparison 2026

ARSSF yields 7.37% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARSSF wins by $71.2K in total portfolio value
10 years
ARSSF
ARSSF
● Live price
7.37%
Share price
$0.68
Annual div
$0.05
5Y div CAGR
25.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$117.1K
Annual income
$31,579.87
Full ARSSF calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — ARSSF vs KMB

📍 ARSSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARSSFKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARSSF + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ARSSF pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARSSF
Annual income on $10K today (after 15% tax)
$626.84/yr
After 10yr DRIP, annual income (after tax)
$26,842.89/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, ARSSF beats the other by $22,403.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARSSF + KMB for your $10,000?

ARSSF: 50%KMB: 50%
100% KMB50/50100% ARSSF
Portfolio after 10yr
$81.5K
Annual income
$18,401.11/yr
Blended yield
22.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

ARSSF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
0.9
Piotroski
5/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARSSF buys
0
KMB buys
0
No recent congressional trades found for ARSSF or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARSSFKMB
Forward yield7.37%5.25%
Annual dividend / share$0.05$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR25.7%17%
Portfolio after 10y$117.1K$45.9K
Annual income after 10y$31,579.87$5,222.34
Total dividends collected$85.6K$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldHold

Year-by-year: ARSSF vs KMB ($10,000, DRIP)

YearARSSF PortfolioARSSF Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$11,627$926.99$11,314$614.45+$313.00ARSSF
2$13,707$1,266.18$12,867$760.19+$840.00ARSSF
3$16,420$1,753.57$14,713$945.27+$1.7KARSSF
4$20,037$2,467.78$16,924$1,181.90+$3.1KARSSF
5$24,978$3,537.70$19,596$1,486.64+$5.4KARSSF
6$31,907$5,180.65$22,850$1,882.16+$9.1KARSSF
7$41,915$7,774.39$26,849$2,399.80+$15.1KARSSF
8$56,846$11,997.78$31,812$3,083.36+$25.0KARSSF
9$79,941$19,115.70$38,033$3,994.72+$41.9KARSSF
10$117,117$31,579.87$45,918$5,222.34+$71.2KARSSF

ARSSF vs KMB: Complete Analysis 2026

ARSSFStock

Assura plc, a constituent of the FTSE 250 and the EPRA* indices, is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington, works with GPs, health professionals and the NHS to create outstanding spaces for health services in our communities. At 30 September 2020, Assura's property portfolio was valued at £2,259 million.

Full ARSSF Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this ARSSF vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARSSF vs SCHDARSSF vs JEPIARSSF vs OARSSF vs KOARSSF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.